Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with lowtotal serum PSA
Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with lowtotal serum PSA
复制标题
DOI：
10.1002/pros.20717
复制
发表时间：
2008-03-01
期刊：
影响因子：
2.8
通讯作者：
Sarma, Aruna V.
中科院分区：
文献类型：
--
作者：
Macoska, Jill A.;Begley, Lesa A.;Sarma, Aruna V.
背景随着年龄的增长，前列腺增生（BPH）和前列腺癌（PCa）的发病率和患病率均呈上升趋势。我们的实验室最近表明，趋化因子CXCL5和CXCL12，通常作为炎症介质，分泌在更高的水平由老化的前列腺基质成纤维细胞和前列腺基质成纤维细胞和上皮细胞引起增殖反应。由于CXCL5和CXCL12都是分泌性分子，我们假设它们在患者血清中的水平可能作为区分BPH和PCa的生物标志物。使用夹心ELISA法测定了51名血清PSA值较低的男性的血清CXCL 5和CXCL 12水平
BACKGROUND. The incidence and prevalence of both benign prostatic hypertrophy (BPH) and prostate cancer (PCa) increase with the aging process. Our laboratory recently showed that the chemokines CXCL5 and CXCL12, which normally function as inflammatory mediators, are secreted at higher levels by aging prostate stromal fibroblasts and elicit proliferative responses from both prostate stromal fibroblast and epithelial cells. Because both CXCL5 and CXCL12 are secreted molecules, we hypothesized that their levels in patient serum might serve as biomarkers to distinguish between BPH and PCa.METHODS. Serum CXCL5 and CXCL12 levels were determined using sandwich ELISAs for 51 men demonstrating low serum PSA values of